hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06354101 id: CorEvitas-VITALITY briefTitle: The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study. overallStatus: WITHDRAWN date: 2023-07-01 date: 2023-07-01 date: 2023-07-01 date: 2024-04-09 date: 2024-04-09 name: CorEvitas class: NETWORK name: Eli Lilly and Company briefSummary: The purpose of this registry study is to learn more about metabolic health. The information gathered will be used to support research on the natural history of obesity and weight related diseases, their treatments, and how it affects overall health. Approximately 15,000 participants who are overweight or have obesity with or without metabolic diseases are expected to participate in this registry study. conditions: Metabolic Health studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 0 type: ACTUAL name: Tirzepatide name: Semaglutide measure: Main Objective of Registry sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06354088 id: AAAU9636 briefTitle: Human Models of Selective Insulin Resistance: Alpelisib, Part I overallStatus: RECRUITING date: 2024-04-24 date: 2026-05 date: 2026-12 date: 2024-04-09 date: 2024-04-29 name: Columbia University class: OTHER name: University of California, Berkeley briefSummary: The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin. Researchers will compare the impact of single doses of both alpelisib and placebo (inert non-drug) in random order (like flipping a coin) in study participants. Participants will be asked to stay twice overnight in the hospital, take single doses of alpelisib and placebo (one or the other on each of the two hospital stays), and receive intravenous (into the vein) infusions of non-radioactive "tracer" molecules that allow researchers to measure the production of glucose (sugar) and fats by the liver. Measurements will be done both overnight, while participants are asleep and fasting (not eating or drinking other than water) and while consuming a standardized diet of nutritional beverages during the following day.
The objective is to evaluate the effect of lowering insulin levels, while maintaining constant mild hyperglycemia, on plasma glucose and lipid levels. conditions: Insulin Resistance conditions: Prediabetic State conditions: Overweight and Obesity conditions: Non-Alcoholic Fatty Liver Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 32 type: ESTIMATED name: Alpelisib 300 mg name: Placebo name: [1-13C] sodium acetate name: [6,6-2H2] D-glucose name: Nestlé BOOST Plus measure: Hepatic de novo lipogenesis (DNL) (absolute value) measure: Hepatic de novo lipogenesis (DNL) (relative value) measure: Endogenous glucose production (EGP) (absolute value) measure: Endogenous glucose production (EGP) (relative value) measure: Serum insulin level measure: Plasma glucose level measure: Triglycerides level measure: Free fatty acids level measure: Glucose kinetics: rate of appearance (absolute value) measure: Glucose kinetics: rate of appearance (relative value) measure: Glucose kinetics: rate of disappearance (absolute value) measure: Glucose kinetics: rate of disappearance (relative value) measure: Apolipoprotein B level sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Columbia University Irving Medical Center status: RECRUITING city: New York state: New York zip: 10032 country: United States name: Joshua R Cook, MD, PhD role: CONTACT phone: 212-305-6289 email: jrc2175@cumc.columbia.edu name: Zachary D Sone role: CONTACT phone: 2123059336 email: zds2120@cumc.columbia.edu name: Joshua R Cook, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Blandine Laferrère, MD, PhD role: SUB_INVESTIGATOR name: Henry N Ginsberg, MD role: SUB_INVESTIGATOR name: Julia J Wattacheril, MD role: SUB_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06354075 id: IRBN302024/CHUSTE briefTitle: Evaluation of Patient Information in Interventional Radiology overallStatus: RECRUITING date: 2024-04-01 date: 2026-03 date: 2026-03 date: 2024-04-09 date: 2024-04-10 name: Centre Hospitalier Universitaire de Saint Etienne class: OTHER briefSummary: Interventional radiology is developing. Patient information modalities are also evolving, in particular information videos. conditions: Patient Satisfaction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Questionary measure: to evaluate satisfaction of patient of explanatory videos in interventional radiology measure: To evaluate satisfaction of patient of comic book in interventional radiology sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Chu Saint-Etienne status: RECRUITING city: Saint-Étienne zip: 42055 country: France name: Sylvain GRANGE, MD role: PRINCIPAL_INVESTIGATOR name: Rémi GRANGE, MD role: SUB_INVESTIGATOR lat: 45.43389 lon: 4.39 hasResults: False
nctId: NCT06354062 id: 0305896 briefTitle: Talent Management Intervention Program for First-Line Nurse Managers overallStatus: COMPLETED date: 2022-12-01 date: 2023-04-30 date: 2023-04-30 date: 2024-04-09 date: 2024-04-09 name: Matrouh University class: OTHER briefSummary: Nurse leaders will be required to manage the rapid change in the healthcare system. Talent management training plays a crucial role in preparing nursing leaders and improving their performance in health care systems. conditions: Intervention conditions: Behavior conditions: Knowledge, Attitudes, Practice studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: A quasi-experimental design primaryPurpose: OTHER masking: SINGLE maskingDescription: First Line Nurse Managers received talent Management intervention program whoMasked: PARTICIPANT count: 125 type: ACTUAL name: Talent management intervention program measure: Questionnaire to measure nurse managers' knowledge measure: Questionnaire to measure talent management practice among first line nurse managers. measure: Questionnaire to measure first-line nurse manager job performance sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Nursing, Matrouh University city: Mersa Matruh zip: 002 country: Egypt lat: 31.3529 lon: 27.23725 hasResults: False
nctId: NCT06354049 id: CASE3Z24 briefTitle: Reiki Therapy to Improve Key Symptoms in Integrative Oncology Clinic (REIKI) overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2024-12-31 date: 2025-03-31 date: 2024-04-09 date: 2024-04-09 name: Case Comprehensive Cancer Center class: OTHER briefSummary: The purpose of this research is to investigate the delivery of Reiki to integrative oncology patients and assess its potential for improving cancer-related symptoms in this population. conditions: Cancer Pain conditions: Oncology Pain studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 20 type: ESTIMATED name: Reiki measure: Recruitment rate as measured by the percentage of participants enrolled measure: Retention rate as measured by the number of participants retained until the final survey point measure: Attendance rate as measured by number of sessions attended per 6 sessions measure: Protocol adherence rate as measured by the number of participants treated in manner consistent with the intervention measure: Acceptability as measured by the patient mean of participant satisfaction survey measure: Data completeness rate measure: Patient-reported outcomes as measured by PROMIS-29(Patient-Reported Outcomes Measurement Information System) score measure: Patient-reported outcomes as measured by ESAS(Edmonton Symptom Assessment System) scale sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center city: Cleveland state: Ohio zip: 44106 country: United States lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06354036 id: NCC4465 briefTitle: Transhiatal Tunnel Valvuloplasty for Reconstruction Following the Laparoscopic Proximal Gastrectomy overallStatus: RECRUITING date: 2023-03-01 date: 2025-03-01 date: 2025-03-01 date: 2024-04-09 date: 2024-04-10 name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences class: OTHER briefSummary: Patients who meet the inclusion criteria will undergo laparoscopic proximal gastric cancer radical surgery, and esophagogastric anastomosis will be performed using the ThTV method.
Review the surgical video and record the time for making the extracorporeal muscle flap, tunnel passage time, and anastomosis time. The production time of the muscle flap is based on the electric knife incision of the muscle flap as the starting point, and successfully penetrating the muscle flap as the endpoint. The tunnel passes through time, pulling the residual end of the esophagus, and starting to pass through the gastric muscle flap tunnel as the time starting point. The complete placement of the gastric tube into the lower mediastinum is used as the time endpoint. The anastomosis time is calculated from the first needle of suturing the residual stomach and the posterior wall of the esophagus until the end of the plasma flap suturing. Record perioperative indicators such as surgical time, bleeding volume, and postoperative hospital stay. The definition of anastomotic stenosis is that in gastroscopy, those who cannot pass through the anastomotic site with ultra-fine endoscopy are judged as anastomotic stenosis.
Postoperative pathology was performed using the 8th edition AJCC staging. Follow up every three months after surgery, including blood tests, liver and kidney function, and tumor markers. According to the situation, choose gastroscopy, upper gastrointestinal imaging, and chest abdominal pelvic enhanced CT. Evaluate postoperative reflux symptoms such as heartburn and sternal pain using the Visick grading system. Gastroscopy Los Angeles grading was used to evaluate postoperative reflux esophagitis. conditions: Gastric Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: the Transhiatal Tunnel Valvuloplasty technique measure: The incidence of postoperative reflux esophagitis measure: the incidence of postoperative anastomotic fistula measure: the incidence of anastomotic stenosis sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/ National Clinical Research for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College status: RECRUITING city: Beijing zip: 100021 country: China name: Dongbing R Zhao, M.D. role: CONTACT phone: +86-13901331816 email: dbzhao2003@sina.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06354023 id: IAGH for Osteoarthritis briefTitle: Human Growth Hormone Injections in the Knee Joint to Treat Osteoarthritis overallStatus: NOT_YET_RECRUITING date: 2024-05-08 date: 2025-05-08 date: 2025-05-08 date: 2024-04-09 date: 2024-04-17 name: John Sledge class: OTHER briefSummary: The goal of this clinical trial is to learn if growth hormone injections can be used to treat osteoarthritis (OA) in the knee. Human studies have shown that repeated injections of human growth hormone leads to the production of articular chondrocytes, which are the cells that make up the cartilage in the knee joint. Restoring cartilage in the knee can alleviate pain, improve function, and postpone the need for a joint replacement procedure. The main questions the study aims to answer are:
* Complete treatment surveys before treatment starts and after it is finished. conditions: Osteoarthritis, Knee studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The proposed clinical trial is a single-arm intervention model. Once per week for six weeks, each participant will receive an intra-articular injection of recombinant human growth hormone (rGH) 15 IU in their affected knee. During the treatment course, the participants will use the same knee brace and crutches (as needed) and be given the same exercises to complete at home. They will all be evaluated 8 weeks, 6 months, and 12 months after their initial injection. primaryPurpose: TREATMENT masking: NONE maskingDescription: None, each participant will receive the same treatment count: 23 type: ESTIMATED name: Recombinant human growth hormone measure: Knee Society Score measure: Kellgren-Lawrence Grading Scale measure: Serum IGF-1 Levels sex: ALL minimumAge: 18 Years maximumAge: 72 Years stdAges: ADULT stdAges: OLDER_ADULT facility: BioShift Life Sciences city: Santa Monica state: California zip: 90404 country: United States name: Maggie Phillips role: CONTACT phone: 301-655-4651 email: maggie@bioshift.com lat: 34.01945 lon: -118.49119 hasResults: False
nctId: NCT06354010 id: SENS-NH02 briefTitle: Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis acronym: SONG overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-07 date: 2027-07 date: 2024-04-09 date: 2024-04-09 name: Sensorion class: INDUSTRY briefSummary: The purpose of this study is to characterize and assess the evolution of hearing impairment of patients with adulthood-onset bilateral sensorineural hearing loss carrying mutations on GJB2 gene. conditions: Sensorineural Hearing Loss, Bilateral studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 100 type: ESTIMATED name: Genotyping name: Audiological assessments measure: Evolution of hearing impairment of adult patients with early-onset presbycusis carrying mutations in GJB2 gene. measure: Evolution of hearing impairment of adult patients with early-onset presbycusis carrying mutations in GJB2 gene measure: Genetic characteristics of adult patients with early-onset presbycusis measure: Audiological characteristics of adult patients with early-onset presbycusis measure: Mood evaluation in adult patients with early-onset presbycusis carrying mutations in GJB2 gene sex: ALL minimumAge: 30 Years maximumAge: 55 Years stdAges: ADULT facility: CHU Gui de Chauliac city: Montpellier zip: 34295 country: France name: Frederic Venail, Pr role: CONTACT lat: 43.61092 lon: 3.87723 hasResults: False
nctId: NCT06353997 id: 2024000099 briefTitle: Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2029-06 date: 2024-04-09 date: 2024-04-09 name: Providence Health & Services class: OTHER name: Inhibrx, Inc. briefSummary: This is a Phase II trial to assess feasibility of pembrolizumab + INBRX-106 as a chemotherapy-sparing neoadjuvant therapy. One therapeutic arm is being evaluated to provide an informal comparison of pharmacodynamic and clinical effects of concurrent dosing schedule. conditions: Triple Negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Pembrolizumab name: INBRX-106 measure: Pathological response (post-IO) measure: Pathological response (post-chemotherapy) measure: IO-path response assessed prior to Cycle 2 measure: Volumetric response measure: Event free survival measure: Overall survival measure: Toxicity profile sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ellison Institute of Technology (EITM) city: Los Angeles state: California zip: 90064 country: United States name: Reva Basho, MD role: CONTACT phone: 310-272-7640 lat: 34.05223 lon: -118.24368 facility: Providence Portland Cancer Institute - Franz Clinic city: Portland state: Oregon zip: 97213 country: United States name: Nicole Moxon, RN role: CONTACT email: canrsrchstudies@providence.org name: Alison Conlin, MD role: SUB_INVESTIGATOR name: Evelyn Brosnan, MD role: SUB_INVESTIGATOR name: Evie Hobbs, MD role: SUB_INVESTIGATOR name: Rui Li, MD, PhD role: SUB_INVESTIGATOR name: Sasha Stanton, MD, PhD role: SUB_INVESTIGATOR name: Zheng Topp, MD role: SUB_INVESTIGATOR name: Amy Hartman, NP role: SUB_INVESTIGATOR name: Kathleen Dronkowski, NP role: SUB_INVESTIGATOR name: Kimberlie Dame, NP role: SUB_INVESTIGATOR name: Molly Davis, NP role: SUB_INVESTIGATOR name: RaYoung Chung, NP role: SUB_INVESTIGATOR name: Roxanne Griswold, NP role: SUB_INVESTIGATOR lat: 45.52345 lon: -122.67621 facility: Providence St. Vincent Medical Center city: Portland state: Oregon zip: 97225 country: United States name: Nicole Moxon, RN role: CONTACT email: canrsrchstudies@providence.org name: David Page, MD role: PRINCIPAL_INVESTIGATOR lat: 45.52345 lon: -122.67621 facility: Swedish Cancer Institute city: Seattle state: Washington zip: 98104 country: United States name: Danielle File, MD role: CONTACT phone: 206-386-3900 lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06353984 id: Minimeal 1.0 briefTitle: Effects of In-between Meal Products on Cognitive Function in Older Adults acronym: Minimeal overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2025-12 date: 2025-12 date: 2024-04-09 date: 2024-04-09 name: Örebro University, Sweden class: OTHER briefSummary: The overall aim of the present 9-week intervention study is to determine how a healthy drinkable in between meal affects cognitive function and brain activity in healthy adults 70 years and older. Secondary, the study also investigates the impact of the intervention on low grade inflammation, immune function, gut health, body composition, physical function, and well-being as secondary or exploratory outcomes. The present study has as the potential to prevent or slow down the onset of cognitive decline as it targets healthy older adults and gives additional insight regarding secondary and exploratory outcomes. conditions: Cognitive Function studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Three-arm randomized controlled trial that includes a double-blinded, two-armed intervention and a non-blinded control arm without any intervention primaryPurpose: PREVENTION masking: TRIPLE maskingDescription: Investigators and participants are partly blinded as the control group receives no placebo product whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 114 type: ESTIMATED name: Minimeal product name: Reference product measure: Functional brain activity measure: Fasting blood glucose/insulin measure: Blood fats/lipid status measure: Interleukin-6 measure: High-sensitivity C-reactive protein measure: Tumor necrosis factor measure: Interferon-gamma measure: Zonulin measure: Intestinal fatty-acid binding protein measure: Cognitive function measure: Magnetic resonance imaging (MRI) measure: The Perceived Stress Scale measure: Hospital Anxiety and Depression Scale measure: SF 36 measure: Western Ontario and McMaster Osteoarthritis Index measure: Clinical Outcomes in Routine Evaluation measure: Gastrointestinal Symptoms Rating Scale measure: Pittsburgh Sleep Quality Index measure: International Physical Activity Questionnaire for the Elderly short form measure: Historical Physical Activity Questionnaire measure: Food frequency questionnaire measure: Physical activity measure: Muscle mass measure: Fat mass measure: Body mass index measure: Waist circumference measure: Aerobic capacity measure: Balance measure: 30-sec repeated chair raise measure: Maximal leg strength measure: Maximal handgrip strength sex: ALL minimumAge: 70 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06353971 id: JSP-CP-010 id: 2023-507534-24 type: EUDRACT_NUMBER briefTitle: A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines acronym: SPOTLIGHT overallStatus: RECRUITING date: 2024-03-18 date: 2025-04-21 date: 2025-08-04 date: 2024-04-09 date: 2024-04-10 name: Jasper Therapeutics, Inc. class: INDUSTRY briefSummary: This is an open-label, single ascending dose Phase 1b/2a trial to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with Cold Urticaria (ColdU) or Symptomatic Dermographism (SD), who remain symptomatic despite treatment with H1 antihistamines. The trial will explore two ascending dose levels which will be tested in two sequential cohorts. conditions: Chronic Inducible Urticaria studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: This is an open-label, single ascending dose, Phase 1b/2a trial.
Cohort 1 follows a 3+3 design and will be treated with a single 40mg dose. Cohort 2 will be treated with a single 120mg dose. primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: Briquilimab measure: Incidence and severity of treatment emergent AEs/SAEs [safety and tolerability] of a single dose of briquilimab in patients with ColdU or SD who remain symptomatic despite the use of H1 antihistamines. measure: Preliminary efficacy of briquilimab sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Charité - University Clinic Berlin status: RECRUITING city: Berlin zip: 12203 country: Germany lat: 52.52437 lon: 13.41053 facility: University Hospital Dresden status: RECRUITING city: Dresden zip: 01307 country: Germany lat: 51.05089 lon: 13.73832 facility: Medical University Hannover status: NOT_YET_RECRUITING city: Hannover zip: 30625 country: Germany lat: 52.37052 lon: 9.73322 facility: University Clinic Schleswig-Holstein status: RECRUITING city: Lübeck zip: 23538 country: Germany lat: 53.86893 lon: 10.68729 hasResults: False
nctId: NCT06353958 id: MiSaver PIIa briefTitle: MiSaver® Stem Cell Treatment for Acute Myocardial Infarction acronym: MiSaver® overallStatus: COMPLETED date: 2023-01-01 date: 2023-12-31 date: 2023-12-31 date: 2024-04-09 date: 2024-04-09 name: Honya Medical Inc class: INDUSTRY name: Chung Shan Medical University briefSummary: Despite advancements in treatments, cardiovascular diseases, especially acute myocardial infarction (AMI), remain significant health concerns. This study hypothesized that stem cells could improve left ventricular function post-AMI. An open-label trial was initiated to assess the safety and feasibility of intravenous infusion of ABO blood group-matched allogeneic umbilical cord blood stem cells (USC) prefabricated into MiSaver (Myocardial Infarction Saver) in AMI patients.
Secondary outcomes evaluated changes in left ventricular ejection fraction (LVEF) from baseline to 12 months post-treatment. A retrospective study compared eligible controls with low and middle dosage groups. conditions: Acute Myocardial Infarction studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 30 type: ACTUAL name: MiSaver measure: Safety and adverse events events measure: Efficacy on ventricular ejection fraction (LVEF) improvement sex: ALL minimumAge: 41 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chung Shan Medical University Hospital city: Taichung country: Taiwan lat: 24.1469 lon: 120.6839 hasResults: False